Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. [electronic resource]
Producer: 20170821Description: 1219-1227 p. digitalISSN:- 1468-2060
- Adult
- Aged
- Antihypertensive Agents -- therapeutic use
- Disease Progression
- Double-Blind Method
- Drug Therapy, Combination
- Edema -- chemically induced
- Female
- Humans
- Hypertension, Pulmonary -- drug therapy
- Lupus Erythematosus, Systemic -- complications
- Male
- Middle Aged
- Mixed Connective Tissue Disease -- complications
- Phenylpropionates -- therapeutic use
- Phosphodiesterase 5 Inhibitors -- therapeutic use
- Pyridazines -- therapeutic use
- Scleroderma, Systemic -- complications
- Tadalafil -- therapeutic use
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.